Flare Therapeutics Presents Data at AACR 2024 Annual Meeting Characterizing PPARG-Derived Immune Cel

-- Data support the potential to explore lead Phase 1 monotherapy asset FX-909 in combination with an anti-PD1 agent -- CAMBRIDGE, Mass., April 9, 2024 /PRNewswire/ ... Read more

Bron:

Health